LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage

Translational Psychiatry

Volumn 5, Issue , 2015, Pages e541-

  Mirendil, H ^a   Thomas, E A ^a   De Loera, C ^a   Okada, K ^b   Inomata, Y ^b   Chun, J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; LYSOPHOSPHATIDIC ACID; PARVALBUMIN; TYROSINE 3 MONOOXYGENASE; LYSOPHOSPHOLIPID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN FUNCTION; BRAIN HEMORRHAGE; CALCIUM SIGNALING; CELL SURFACE; CONTROLLED STUDY; EMBRYO; ENDOCYTOSIS; FEMALE; GENE DELETION; GENE EXPRESSION; HYDROCEPHALUS; HYPERACTIVITY; HYPOACTIVITY; LIPID METABOLISM; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRENATAL DISORDER; PRENATAL EXPOSURE; PREPULSE INHIBITION; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; DISEASE MODEL; EMBRYOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; INTRACRANIAL HEMORRHAGES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84926312321     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.33     Document Type: Article

References (74)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
2. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007; 97: 51-59.
3. Indredavik MS, Vik T, Evensen KA, Skranes J, Taraldsen G, Brubakk AM. Perinatal risk and psychiatric outcome in adolescents born preterm with very low birth weight or term small for gestational age. J Dev Behav Pediatr 2010; 31: 286-294.
4. Hamlyn J, Duhig M, McGrath J, Scott J. Modifiable risk factors for schizophrenia and autism-shared risk factors impacting on brain development. Neurobiol Dis 2013; 53: 3-9.
5. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 2002; 159: 1080-1092.
6. Hultman CM, Sparén P, Takei N, Murray RM, Cnattingius S. Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. BMJ 1999; 318: 421-426.
7. Boog G. Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? Eur J Obstet Gynecol Reprod Biol 2004; 114: 130-136.
8. Rosanoff AJ, Handy LM, Plesset IR, Brush S. The etiology of so-called schizophrenic psychoses, with special reference to their occurrence in twins. Am J Psychiatry 1934; 91: 247-286.
9. Torrey EF, Hersh SP, McCabe KD. Early childhood psychosis and bleeding during pregnancy. A prospective study of gravid women and their offspring. J Autism Child Schizophr 1975; 5: 287-297.
10. Meyer U. Prenatal Poly(I:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307-315.
11. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-680.
12. Cummings R, Zhao Y, Jacoby D, Spannhake EW, Ohba M, Garcia JG et al. Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kB activation and interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem 2004; 279: 41085-41094.
13. Li ZG, Yu ZC, Yu YP, Ju WP, Wang DZ, Zhan X et al. Lysophosphatidic acid level and the incidence of silent brain infarction in patients with nonvalvular atrial fibrillation. Int J Mol Sci 2010; 11: 3988-3998.
14. Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW et al. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl Med 2011; 3: 87-99.
15. Mirendil H Lin M-E Chun J. Lysophosphatidic acid (LPA) receptor signaling. Chun, J, Hla, T, Spiegel, S, Moolenaar, W (eds). Lysophospholipid Receptors: Signaling and Biochemistry. John Wiley & Sons: Hoboken, NJ, USA, 2013. 1-39.
16. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-186.
17. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002; 277: 48737-48744.
18. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009; 174: 1264-1279.
19. Hao F, Tan M, Wu DD, Xu X, Cui MZ. LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38alpha-mediated pathway. Am J Physiol Heart Circ Physiol 2010; 298: H974-H983.
20. Dubin A. E, Herr D. R, Chun J. Diversity of lysophosphatidic acid receptormediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci 2010; 30: 7300-7309.
21. Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010; 30: 1270-1287.
22. Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27: 10695-10702.
23. Kuroda K, Yamada S, Tanaka M, Iizuka M, Yano H, Mori D et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum Mol Genet 2011; 20: 4666-4683.
24. Chesworth R, Downey L, Logge W, Killcross S, Karl T. Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res 2012; 226: 218-223.
25. Desbonnet L, Waddington JL, O'Tuathaigh CMP. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes? Behav Brain Res 2009; 204: 258-273.
26. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun 2010; 24: 881-897.
27. Rana SA, Aavani T, Pittman QJ. Sex effects on neurodevelopmental outcomes of innate immune activation during prenatal and neonatal life. Horm Behav 2012; 62: 228-236.
28. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012; 2012: 916198.
29. Ohuchi H, Hamada A, Matsuda H, Takagi A, Tanaka M, Aoki J et al. Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev Dyn 2008; 237: 3280-3294.
30. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994-1005.
31. Santin LJ, Bilbao A, Pedraza C, Matas-Rico E, López-Barroso D, Castilla-Ortega E et al. Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav 2009; 8: 772-784.
32. Harrison SM, Reavill C, Brown G, Brown JT, Cluderay JE, Crook B et al. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 2003; 24: 1170-1179.
33. Castilla-Ortega E, Sánchez-López J, Hoyo-Becerra C, Matas-Rico E, Zambrana-Infantes E, Chun J et al. Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor. Neurobiol Learn Mem 2010; 94: 73-82.
34. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18: 551-553.
35. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V et al. Engagement of S1P (1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest 2011; 121: 2290-2300.
36. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011; 108: 751-756.
37. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007; 282: 9082-9089.
38. Reif A, Schmitt A, Fritzen S, Lesch KP. Neurogenesis and schizophrenia: dividing neurons in a divided mind? Eur Arch Psychiatry Clin Neurosci 2007; 257: 290-299.
39. Allen N, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 4: 827-834.
40. Jia P, Sun J, Guo A. Y, Zhao Z. SZGR: a comprehensive schizophrenia gene resource. Mol Psychiatry 2010; 15: 453-462.
41. Higgs B, Elashoff M, Richman S, Barci B. An online database for brain disease research. BMC Genomics 2006; 7: 70.
42. Yanagi M, Southcott S, Lister J, Tamminga C. Animal models of schizophrenia emphasizing construct validity. Prog Mol Biol Transl Sci 2012; 105: 411-444.
43. Herr KJ, Herr DR, Lee CW, Noguchi K, Chun J. Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling. Proc Natl Acad Sci USA 2011; 108: 15444-15449.
44. Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to propsychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology 2009; 34: 2305-2322.
45. Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, André CB et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 2012; 37: 2580-2592.
46. Ramsey JM, Schwarz E, Guest PC, van Beveren NJ, Leweke FM, Rothermundt M et al. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One 2013; 8: e78729.
47. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci 2002; 966: 131-142.
48. McCombe PA, Greer JM, Mackay IR. Sexual dimorphism in autoimmune disease. Curr Mol Med 2009; 9: 1058-1079.
49. Graler MH, Goetzl EJ. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 2002; 1582: 168-174.
50. Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE et al. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J Clin Invest 2014; 124: 2571-2584.
51. Garcia-Fernandez M, Castilla-Ortega E, Pedraza C, Blanco E, Hurtado-Guerrero I, Barbancho MA et al. Chronic immobilization in the malpar1 knockout mice increases oxidative stress in the hippocampus. Int J Neurosci 2012; 122: 583-589.
52. Pedraza C, Sánchez-López J, Castilla-Ortega E, Rosell-Valle C, Zambrana-Infantes E, García-Fernández M et al. Fear extinction and acute stress reactivity reveal a role of LPA1 receptor in regulating emotional-like behaviors. Brain Struct Funct 2013; 219: 1659-1672.
53. Santin LJ, Bilbao A, Pedraza C, Matas-Rico E, López-Barroso D, Castilla-Ortega E et al. Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav 2009; 8: 772-784.
54. Levelt CN, Hubener M. Critical-period plasticity in the visual cortex. Annu Rev Neurosci 2012; 35: 309-330.
55. Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol 2014; 171: 3575-3594.
56. Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res 2014; 14: in press.
57. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 2011; 12: 213-228.
58. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.
59. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242.
60. McNally JM, McCarley RW, Brown RE. Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations. Curr Psychiatry Rep 2013; 15: 346.
61. Lin C-H, Lane H-Y, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012; 100: 665-677.
62. Shano S, Moriyama R, Chun J, Fukushima N. Lysophosphatidic acid stimulates astrocyte proliferation through LPA1. Neurochem Int 2008; 52: 216-220.
63. Pilpel Y, Segal M. The role of LPA1 in formation of synapses among cultured hippocampal neurons. J Neurochem 2006; 97: 1379-1392.
64. Cunningham MO, Hunt J, Middleton S, LeBeau FE, Gillies MJ, Davies CH et al. Regionspecific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 2006; 26: 2767-2776.
65. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M et al. Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell 2009; 138: 1222-1235.
66. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci USA 2005; 102: 6027-6032.
67. Sun Y, Kim N-H, Yang H, Kim S-H, Huh S-O. Lysophosphatidic acid induces neurite retraction in differentiated neuroblastoma cells via GSK-3β activation. Mol Cells 2011; 31: 483-489.
68. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3b/b-catenin signaling. Cell 2009; 136: 1017-1031.
69. Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007; 30: 142-149.
70. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009; 204: 313-321.
71. Gardner MR. Outcomes in children experiencing neurologic insults as preterm neonates. Pediatr Nurs 2005; 31: 448, 451-446.
72. Kinney DK, Yurgelun-Todd DA, Tohen M, Tramer S. Pre- and perinatal complications and risk for bipolar disorder: a retrospective study. J Affect Disord 1998; 50: 117-124.
73. Preti A, Cardascia L, Zen T, Pellizzari P, Marchetti M, Favaretto G et al. Obstetric complications in patients with depression-a population-based case-control study. J Affect Disord 2000; 61: 101-106.
74. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry 2009; 195: 7-14.